# A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Source: https://onco.cc/trials/nct05053880/  
OnCo record `nct05053880` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in glioma & glioblastoma, run by Accendatech USA Inc., active and no longer recruiting.

## Summary

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme is a phase 1/2 interventional study registered as NCT05053880 by Accendatech USA Inc., with 48 participants enrolled, started 2021-09-22 and due to reach its primary completion in 2024-10-25. Interventions recorded: ACT001 and ACT001 + Pembrolizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05053880
- Phase: 1/2
- Setting: A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
- Sponsor: Accendatech USA Inc.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT05053880: https://clinicaltrials.gov/study/NCT05053880

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05053880.json